Mys­te­ri­ous Or­biMed-backed biotech nears $100M in fund­ing, hints at plans to go af­ter ‘un­drug­gable 3.0’

In Jan­u­ary, Al­terome launched from stealth — but re­mained quite stealthy. While the biotech put out a press re­lease for its $64 mil­lion Se­ries A, led by Or­biMed, it launched with­out a web­site and didn’t elab­o­rate on its sci­ence be­yond “al­ter­ation-spe­cif­ic tar­get­ed ther­a­pies for the treat­ment of can­cer.”

But with an ad­di­tion­al $35 mil­lion — bring­ing its to­tal Se­ries A to $99 mil­lion — Al­terome ap­pears more will­ing to share. For one, it now has a web­site, al­though the page doesn’t of­fer more than the bare-bones de­tails on the sci­ence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER